A
ALP Bio
Founded in 2025 by CEO Dr. Christian Vahlensieck alongside co-founders Anatol Ehrlich, Punit Mehra, and Lucas Schaus, ALP Bio is building a platform that fuses human immune organoid readouts with generative AI. Its mission is to surface immunogenicity risk earlier in antibody development, helping antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
Funding
Every round, secondary, debt facility or acquisition involving ALP Bio that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see every AI company on Lounge with revenue, funding, valuation and investors, searchable and sortable, plus CSV exports. Plans start at $19/mo.
See plans →Log in